Propeller Health, provider of an FDA-cleared digital health solution for improving outcomes in asthma and chronic obstructive pulmonary disease (COPD), today announced a development agreement and R&D collaboration with GSK for its Ellipta® inhaler, the pharmaceutical company’s innovative, patented, dry powder inhaler. Read the full story here.
- From Denmark to DeForest, 55 entries advance in 2021 Wisconsin Governor’s Business Plan ContestMarch 4, 2021
- Charter Communications Launches New Multiyear, Multibillion-Dollar Initiative To Expand Broadband Availability To Over 1 Million New Customer LocationsMarch 4, 2021
- InsideWis: COVID-19 hibernation is coming to an end: Some thoughts on risk managementMarch 3, 2021
- Healthcare IT experts to discuss digital health at virtual March 17 Tech SummitMarch 3, 2021
- WisconsinINNO: Milwaukee angel investors form new network to invest in Wisconsin, Midwest startupsMarch 2, 2021